Industry veteran brings more than 30 years of experience launching therapies for neurological diseases, including Huntington’s disease, and will prepare Skyhawk for the launch of SKY-0515 as early as 2027.

BOSTON, Mar 11 — Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies to modulate critical RNA targets for a series of challenging neurological diseases, announces the appointment of Aaron Deves as Chief Commercial Officer. Mr. Deves brings more than 30 years of experience commercializing therapies for neurological disorders, including for chorea associated with Huntington’s disease (HD) with AUSTEDO^®. SKY-0515 is Skyhawk’s lead program and is being developed as a potential disease-modifying therapy for Huntington’s disease.

“Skyhawk may receive accelerated approval for SKY-0515 in Australia within the next twelve months, and in other major markets during 2027,” said Bill Haney, CEO of Skyhawk Therapeutics. “Aaron’s 30 years of experience successfully building commercial teams and launching innovative drugs for challenging neurological conditions helps prepare Skyhawk to bring a much-needed disease-modifying treatment to patients with Huntington’s disease as quickly as possible – pending additional clinical results and regulatory approvals.”

“I am incredibly excited to join Skyhawk,” said Aaron Deves, Chief Commercial Officer of Skyhawk Therapeutics. “Skyhawk’s Huntington’s disease program can be the cornerstone of a powerful commercial neuro business.  And the company’s rich pre-clinical pipeline of RNA targeting drug programs addresses the most impressive set of challenging neurological conditions I’ve seen in my career – and does so with small molecules that are often the most patient friendly modality. I’m thrilled to join the company to prepare for the launch of SKY-0515 and to help ensure the broadest number of patients can access this important therapy.“